Strong Progress in Key Focus Areas
FMC made significant advancements in four critical focus areas: aligning channel inventory levels, implementing a post-patent strategy, establishing a new route to market in Brazil, and ensuring resources for the growth portfolio, particularly with Rynaxypyr.
New Product Launches and Market Expansion
FMC introduced new formulations of Rynaxypyr and Bifenthrin, with expected sales of $200-$250 million in 2025. Additionally, the company is launching new products in Brazil, targeting large corn and soybean growers, expected to provide a multi-hundred million dollar growth opportunity.
Growth in Plant Health Segment
The Plant Health business outperformed the portfolio with sales up 1% versus the prior year, driven by biologicals. The recent registration of Sofero pheromone in Brazil is expected to boost sales further.
Positive Outlook for Second Half of 2025
FMC expects strong growth in the second half of 2025, driven by new products, a new route to market in Brazil, and improved channel inventory levels. The company anticipates a revenue growth of 7% and EBITDA growth of 11% in the second half.